Harvard Drug Group has agreed to pay $8 million to settle claims that it sold a large volume of prescription drugs that ended up being used illegally, according to a Detroit Free Press report.
Harvard was accused of failing to identify and failing to report suspicious prescription drug orders to the Drug Enforcement Administration. Both actions violate the Controlled Substances Act. The government has agreed to suspend the final $2 million payment if the company shows it has an effective regulatory compliance program.
A DEA investigation showed Harvard received more than 1,000 suspicious orders for certain narcotics between 2009 and 2010, including oxycodone.
Read the Detroit Free Press report on Harvard Drug Group.
Read about other pharmaceutical companies involved in fraud lawsuits:
- CVS Pays $17M To Settle Medicaid Fraud Allegations
- Wisconsin's Ongoing Lawsuit Against Drugmakers Reaches Nearly $13M in Settlements
Harvard was accused of failing to identify and failing to report suspicious prescription drug orders to the Drug Enforcement Administration. Both actions violate the Controlled Substances Act. The government has agreed to suspend the final $2 million payment if the company shows it has an effective regulatory compliance program.
A DEA investigation showed Harvard received more than 1,000 suspicious orders for certain narcotics between 2009 and 2010, including oxycodone.
Read the Detroit Free Press report on Harvard Drug Group.
Read about other pharmaceutical companies involved in fraud lawsuits:
- CVS Pays $17M To Settle Medicaid Fraud Allegations
- Wisconsin's Ongoing Lawsuit Against Drugmakers Reaches Nearly $13M in Settlements